Neptune Pharma's Azasure Sea Lice Treatment Approved for Use on Farmed Salmon in Chile

Santiago, Chile, August 13, 2015 (Newswire.com) - Neptune Pharma announced today their highly successful generic sea lice product containing Azamethiphos for use on farmed salmon​ was approved by Chile's Servicio Agrícola y Ganadero (SAG) in July 2015. Azasure will be available in Chile by August 2015.

Since the Norwegian launch of Azasure in  January 2014, Azasure has taken a significant market share from Benchmark Holding's Salmosan. In 2014 Azasure managed to reduce Salmosan's Norwegian market share to under 40%.

The launch of Azasure in Chile signals the end to many years of challenging work within our organisation globally. After such a long wait, we're happy to get from the planning phase into the commercial phase.

Adrian Endacott, Chief Executive Officer

Neptune Pharma hopes to replicate the success of their Norwegian launch in Chile. Neptune are planning to gain significant market share from Benchmark Holdings Plc's competing product named Bylice in Chile.